论文部分内容阅读
目的探讨胸腺肿瘤临床病理学特点。方法分析31例胸腺肿瘤的临床病理学特点和随访资料。结果31例胸腺肿瘤中,A型2例(6.45%),AB型7例(22.58%),B1型3例(9.68%),B2型12例(38.71%),B3型5例(16.13%),胸腺癌2例(6.45%)。Masaoka临床分期:Ⅰ期11例(35.48%),Ⅱ期9例(29.03%),Ⅲ期6例(19.36%),Ⅳa期5例(16.13%)。组织学分型与临床分期具有显著的相关性。免疫组化结果p53阳性18例(58.06%),Ki-67阳性15例(48.39%)。结论WHO组织学分型能反映胸腺瘤各亚型的生物学行为,胸腺肿瘤的Masaoka分期是影响胸腺瘤患者生存的最重要的独立预后参数,WHO组织学分型和肿瘤是否切除彻底是影响胸腺瘤患者预后的重要决定因素。
Objective To investigate the clinicopathological features of thymic tumors. Methods 31 cases of thymus tumor clinicopathological features and follow-up data. Results Thirty two cases (6.45%) of type A thymoma, 7 cases of AB type (22.58%), 3 cases of type B1 (9.68%), 12 cases of type B2 (38.71% ), Thymus cancer in 2 cases (6.45%). Masaoka clinical stage: 11 cases (35.48%) in stage I, 9 cases (29.03%) in stage II, 6 cases (19.36%) in stage III and 5 cases (16.13%) in stage IVa. Histological type and clinical stage has a significant correlation. Immunohistochemical results of p53 positive in 18 cases (58.06%), Ki-67 positive in 15 cases (48.39%). Conclusions WHO histological classification can reflect the biological behavior of each subtypes of thymoma. The Masaoka staging of thymoma is the most important independent prognostic factor for the survival of thymoma patients. WHO histological classification and complete removal of the tumor are the major risk factors for thymoma patients Important prognostic factors.